1 Pippias M, Kramer A, Noordzij M, et al. The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary. Clin Kidney J.2017 Apr;10(2):154–69.
2 Heaf J. Current trends in European renal epidemiology.
Clin Kidney J.2017 Apr;10(2):149–53.
3 Ruiz-Hurtado G, Sarafidis P, Fernández-Alfonso MS, et al. Global cardiovascular protection in chronic kidney disease. Nat Rev Cardiol. 2016Oct;13(10):603–8.
4 Wanner C, Inzucchi SE, Lachin JM,et al. EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med.2016 Jul 28;375(4):323–34.
5 Holdsworth SR, Gan PY, Kitching AR. Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol. 2016 Apr;12(4):217–31.
6 Gansevoort RT, Arici M, Benzing T,et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016 Mar;31(3):337–48.
7 Lederer ED. America’s kidney disease epidemic merits congressional attention. The Hill.
Thehill.com/blogs/congress-blog/healthcare/